These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 21593456)

  • 1. High-sensitivity C-reactive protein, obesity, and subclinical atherosclerosis: implications of JUPITER from the MESA study.
    Targher G
    Arterioscler Thromb Vasc Biol; 2011 Jun; 31(6):1251-2. PubMed ID: 21593456
    [No Abstract]   [Full Text] [Related]  

  • 2. Association between obesity, high-sensitivity C-reactive protein ≥2 mg/L, and subclinical atherosclerosis: implications of JUPITER from the Multi-Ethnic Study of Atherosclerosis.
    Blaha MJ; Rivera JJ; Budoff MJ; Blankstein R; Agatston A; O'Leary DH; Cushman M; Lakoski S; Criqui MH; Szklo M; Blumenthal RS; Nasir K
    Arterioscler Thromb Vasc Biol; 2011 Jun; 31(6):1430-8. PubMed ID: 21474823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The JUPITER study].
    Gaspardone A; Maseri A
    G Ital Cardiol (Rome); 2009 May; 10(5):267-70. PubMed ID: 19537439
    [No Abstract]   [Full Text] [Related]  

  • 4. Low-risk older patients (50 years and older) with raised high-sensitivity CRP (hs-CRP) benefit from rosuvastatin therapy: the JUPITER study.
    Cardiovasc J Afr; 2008; 19(6):332-4, discussion 335. PubMed ID: 19104734
    [No Abstract]   [Full Text] [Related]  

  • 5. The editor's roundtable: the JUPITER trial--initial results and clinical implications.
    Ridker PM; Friedewald VE; Davidson MH; Willerson JT; Roberts WC
    Am J Cardiol; 2009 May; 103(10):1417-25. PubMed ID: 19427439
    [No Abstract]   [Full Text] [Related]  

  • 6. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial.
    Ridker PM;
    Circulation; 2003 Nov; 108(19):2292-7. PubMed ID: 14609996
    [No Abstract]   [Full Text] [Related]  

  • 7. The editor's roundtable: JUPITER follow-up.
    Friedewald VE; Ballantyne CM; Davidson MH; Gotto AM; Ridker PM; Roberts WC
    Am J Cardiol; 2011 May; 107(10):1549-57. PubMed ID: 21539951
    [No Abstract]   [Full Text] [Related]  

  • 8. [JUPITER can yield paradigmatic shift in the prevention of cardiovascular disease. Focus on inflammation as a risk factor].
    Olsson AG
    Lakartidningen; 2009 May 20-Jun 2; 106(21-22):1471-5. PubMed ID: 19579435
    [No Abstract]   [Full Text] [Related]  

  • 9. JUPITER study highlights value of anti-inflammatory action of rosuvastatin.
    Cardiovasc J Afr; 2009; 20(3):211. PubMed ID: 19575096
    [No Abstract]   [Full Text] [Related]  

  • 10. Letter by Wells and Eisenberg regarding article, "Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials".
    Wells MT; Eisenberg T
    Circulation; 2010 Dec; 122(23):e575; author reply e577. PubMed ID: 21135368
    [No Abstract]   [Full Text] [Related]  

  • 11. Cardiovascular health. Statin therapy reduces disease in healthy volunteers--but how, exactly?
    Couzin J
    Science; 2008 Nov; 322(5904):1039. PubMed ID: 19008423
    [No Abstract]   [Full Text] [Related]  

  • 12. Letter by Vos et al regarding article, "Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials".
    Vos E; Rose CP; Biron P
    Circulation; 2010 Dec; 122(23):e576; author reply e577. PubMed ID: 21135369
    [No Abstract]   [Full Text] [Related]  

  • 13. The JUPITER Trial: responding to the critics.
    Ridker PM; Glynn RJ
    Am J Cardiol; 2010 Nov; 106(9):1351-6. PubMed ID: 21029837
    [No Abstract]   [Full Text] [Related]  

  • 14. [JUPITER, what now?].
    Perna GP
    G Ital Cardiol (Rome); 2009 Dec; 10(11-12 Suppl 3):33S-38S. PubMed ID: 21298860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [JUPITER study about rosuvastatin and risk of cardiovascular disease. Unclear consequences for the guideline].
    Lubsen J
    Ned Tijdschr Geneeskd; 2009 Feb; 153(6):216-7. PubMed ID: 19271438
    [No Abstract]   [Full Text] [Related]  

  • 16. The numbers are in: statins for the primary prevention of cardiovascular disease in women.
    Duvernoy CS; Blumenthal R
    Circulation; 2010 Mar; 121(9):1063-5. PubMed ID: 20176993
    [No Abstract]   [Full Text] [Related]  

  • 17. [JUPITER study, more reason to give statins as preventive measure - commentary].
    Narkiewicz K
    Kardiol Pol; 2009 Mar; 67(3):346-7. PubMed ID: 19469067
    [No Abstract]   [Full Text] [Related]  

  • 18. Rosuvastatin outcomes study JUPITER closes early due to evidence of benefit.
    Cardiovasc J Afr; 2008; 19(2):117. PubMed ID: 18516361
    [No Abstract]   [Full Text] [Related]  

  • 19. [JUPITER study (2). For now no reason to give statins to more people].
    Koopmans RP
    Ned Tijdschr Geneeskd; 2009 Feb; 153(6):218-9. PubMed ID: 19271439
    [No Abstract]   [Full Text] [Related]  

  • 20. Public health. U.S. panel favors wider use of preventive drug treatment.
    Couzin-Frankel J
    Science; 2010 Jan; 327(5962):130-1. PubMed ID: 20056859
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.